HER-2 overexpression

HER2-high and HER2-low/TNBC breast cancers demonstrate distinct clinicopathologic and molecular profiles. Therapy-associated enrichment of PIK3CA mutations and their association with aggressive behavior underscore their prognostic and therapeutic significance in HER2-positive disease. Further studies are needed to clarify their role in guiding personalized treatment strategies.

P2, N=47, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2025 --> May 2026

Tumour size, blood flow grade, Ki-67 expression, and axillary lymph node ultrasound diagnosis are correlated with axillary lymph node metastasis in IBC. Maximum tumour diameter ≥20 mm and abnormal axillary lymph node ultrasound are significant risk factors.

T297 is located in the middle domain of HSP90, a region that is involved in the interaction of HSP90 with clients. Consistently, structural studies indicate that T297 phosphorylation can indeed favor the chaperone's interaction with HER2, further supporting our hypothesis.

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2028

HER2 IHC 3 + tumors are substantially more likely to achieve pCR following anti-HER2-based NACT than HER2 (2 + )/ISH + tumors, indicating that HER2 expression intensity has predictive relevance. Quantitative HER2 assessment should be integrated into therapeutic planning and trial stratification to optimize outcomes in early-stage HER2-positive BC.

P2, N=43, Not yet recruiting, University of Chicago

This study highlights the Fulvestrant-zinc oxide nanoparticles as a promising therapeutic intervention for HER2-positive breast cancer. By undergoing computational approaches, Network analysis and pharmacogenomics.

P1, N=28, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Apr 2026

P2, N=54, Recruiting, Tel-Aviv Sourasky Medical Center

This review highlights the spectrum of mucin-producing breast lesions, focusing on the above-mentioned entities along with recent molecular updates, potential mimics and diagnostic pitfalls on CNB specimens. Awareness of these entities, a practical approach to their diagnosis, combined with judicious use of immunohistochemistry, are crucial for accurate diagnosis by pathologists, which is in turn essential for guiding clinical decision making for optimal patient outcomes.

DS exerts anti-tumor effects in LUAD by directly regulating ERBB2 expression, inhibiting PI3K/AKT signaling, and disrupting glycolysis. These findings support DS as a promising therapeutic candidate for LUAD.